Friday 29^th September 2023

13:45      Welcome and introduction

Renal Cell Carcinoma (Tobias Klatte, Anna Patrikidou, Ursula Vogl)

14:00      Small renal mass: Surveillance of active treatment? (T. Klatte, Berlin)

14:30      Adjuvant therapy for ccRCC – How to select patients? (U. Vogl, Bellinzona)

15:00      First-line mccRCC: do all patients needs an IO-TKI combination? (A. Patrikidou, Villejuif)

15:50      Coffee break

Testicular Cancer and Penile Cancer (Anja Lorch, Jörg Beyer, Christian Fankhauser)

16:20      Micro-RNA in testicular cancer: how to make best use of the new diagnostic tool? (A. Lorch, Zürich)

16:50      Metastatic germ-cell tumours: Practical tips and tricks in the management of systemic therapy (J. Beyer, Bern)

17:20      Penile cancer: What is the current state of the art? (C. Fankhauser, Luzern)

17:50      Case discussion (Moderation: Chairs)

18:15    Adjourn and Dinner

Saturday 30^th September 2023

Prostate Cancer (Eva Comperat, Robert Förster, Thomas Hermanns, Aurelius Omlin)

08:00      What can the clinicians learn from the pathologist? (E. Comperat, Wien)

08:30      High-risk localized or node positive prostate cancer – the radiation oncologists perspective (R. Förster, Winterthur)                                                                                                  

09:00      High-risk localized or node positive prostate cancer – the urologists perspective (T. Hermanns, Zürich)

09:30      mCRPC: Combination of PARP and ARPI – for all patients or only for Biomarker selected patients? (A. Omlin, Zürich)

10:20      Coffee break

Urothelial Carcinoma (Eva Comperat, Tobias Klatte, Verane Achard, Richard Cathomas)

                Muscle invasive bladder cancer:

10:40      The pathologists view – Can we use the pathology and/or the molecular classification for decision making? (E. Comperat, Wien)

11:10      The urologists view: the bladder must be removed (T. Klatte, Berlin)

11:40      The radiation oncologists view: The bladder must be preserved (V. Achard, Fribourg)

12:10      Standard systemic therapy for muscle invasive urothelial carcinoma 2023 (R. Cathomas, Chur)

12:40      Award for best case presentation (A. Omlin, Zürich)

12:45      End